首页 | 本学科首页   官方微博 | 高级检索  
     


A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia
Authors:Hartmut Döhner  Carsten Müller-Tidow  Michael Lübbert  Walter Fiedler  Alwin Krämer  Jörg Westermann  Gesine Bug  Richard F. Schlenk  Utz Krug  Rainer-Georg Goeldner  James Hilbert  Tillmann Taube  Oliver G. Ottmann
Affiliation:1. Department of Internal Medicine III, University of Ulm, Ulm, Germany;2. Department of Medicine A, University Hospital Muenster, Muenster, Germany;3. Department of Haematology, Oncology and Stem Cell Transplantation, University of Freiburg Medical Centre, Faculty of Medicine, Freiburg, Germany;4. Department of Medicine II, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany;5. Department of Internal Medicine V, University of Heidelberg and German Cancer Research Centre (DKFZ), Heidelberg, Germany;6. Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie, Charité – Universitaetsmedizin Berlin, Berlin, Germany;7. Department of Medicine, Haematology/Oncology, Goethe University, Frankfurt/Main, Germany;8. Biostatistics and Data Sciences, Boehringer Ingelheim International GmbH, Biberach, Germany;9. Clinical Pharmacokinetics/Pharmacodynamics, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA;10. Medicine Therapeutic Area Oncology, Boehringer Ingelheim International GmbH, Biberach, Germany
Abstract:
Keywords:BI 811283  low-dose cytarabine  acute myeloid leukaemia  Aurora B kinase  phase I
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号